For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
NOTE: Please refer to primary antibody product webpage for recommended antibody dilution.
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalent grade water.
Load 20 µl onto SDS-PAGE gel (10 cm x 10 cm).
NOTE: Volumes are for 10 cm x 10 cm (100 cm2) of membrane; for different sized membranes, adjust volumes accordingly.
* Avoid repeated exposure to skin.
posted June 2005
revised June 2020
Protocol Id: 263
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys410 of human GLTSCR2 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Glioma tumor suppressor candidate region gene 2 protein (GLTSCR2), also known as protein interacting with carboxyl terminus-1 (PICT-1), displays tumor suppressor activity, in part, by interacting with the C-terminal region of PTEN and preventing its degradation. Disruption of this interaction upregulates activity of the PI3K/Akt signaling axis and promotes cell transformation (1,2). Further evidence to support the tumor suppressor role of GLTSCR2 lies in the finding that GLTSCR2 is localized to the tumor suppressive region of chromosome 19q, which is subject to lesions in human brain tumors (3). Indeed, research studies have demonstrated that GLTSCR2 harbors nonsense mutations and deletions in glioblastomas, which lead to a decrease in GLTSCR2 protein expression (4). GLTSCR2 has also been shown to exert tumor suppressor activity through its involvement in the nucleolar stress response. Research studies indicate that in response to ribosomal stress, GLTSCR2 translocates from the nucleolus to the nucleoplasm where it binds and stabilizes p53 tumor suppressor, which results in inhibition of cell cycle progression (5).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.